TrialBritish journal of cancer2024

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).

Hiroko Minatogawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.